News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
R-Tech Ueno: Basic Agreement on the Supply of Recombinant Human Serum Albumin
October 18, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573) and Novozymes Biopharma DK A/S (hereinafter referred to as Novozymes) reached a basic agreement today on the supply of recombinant human serum albumin as described below:
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
Europe
MORE ON THIS TOPIC
Layoff Tracker
Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs
May 16, 2025
·
207 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
May 16, 2025
·
2 min read
·
Tristan Manalac
RNA editing
Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline
May 16, 2025
·
2 min read
·
Tristan Manalac
C-suite
UPDATED: With Novo CEO’s Sudden Exit, Analysts Worry ‘There’s Something Pretty Wrong Here’
May 16, 2025
·
5 min read
·
Annalee Armstrong
